MX2015007185A - Uso de eribulina en el tratamiento de cancer de pecho. - Google Patents
Uso de eribulina en el tratamiento de cancer de pecho.Info
- Publication number
- MX2015007185A MX2015007185A MX2015007185A MX2015007185A MX2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A MX 2015007185 A MX2015007185 A MX 2015007185A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- eribulin
- treatment
- subjects
- provides methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261733238P | 2012-12-04 | 2012-12-04 | |
| US201361878204P | 2013-09-16 | 2013-09-16 | |
| PCT/IB2013/002911 WO2014087230A1 (en) | 2012-12-04 | 2013-12-04 | Use of eribulin in the treatment of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015007185A true MX2015007185A (es) | 2017-09-05 |
Family
ID=50031376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007185A MX2015007185A (es) | 2012-12-04 | 2013-12-04 | Uso de eribulina en el tratamiento de cancer de pecho. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140163095A1 (https=) |
| EP (1) | EP2928464A1 (https=) |
| JP (2) | JP6466339B2 (https=) |
| KR (1) | KR20150090921A (https=) |
| AU (2) | AU2013353745A1 (https=) |
| BR (1) | BR112015012731A2 (https=) |
| CA (1) | CA2892780A1 (https=) |
| IL (1) | IL239007B (https=) |
| MX (1) | MX2015007185A (https=) |
| RU (1) | RU2689977C2 (https=) |
| WO (1) | WO2014087230A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2522663B1 (en) | 2004-06-03 | 2015-04-01 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of halichondrin B |
| ES2593027T3 (es) | 2009-03-30 | 2016-12-05 | Eisai R&D Management Co., Ltd. | Composición liposomal |
| DK2468281T3 (en) | 2009-08-19 | 2016-03-21 | Eisai R&D Man Co Ltd | Quinolinderivatholdig pharmaceutical composition |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| MX2015007185A (es) * | 2012-12-04 | 2017-09-05 | Eisai R&D Man Co Ltd | Uso de eribulina en el tratamiento de cancer de pecho. |
| JP6644479B2 (ja) * | 2014-06-24 | 2020-02-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がん治療のための併用療法としてのエリブリンとｓ−１（もしくは５−ｆｕ）の使用 |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| CA2978311A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| JP2020508315A (ja) * | 2017-02-20 | 2020-03-19 | ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ | がんを治療するための薬剤組合せ |
| EP3624800A4 (en) | 2017-05-16 | 2021-02-17 | Eisai R&D Management Co., Ltd. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
| US20200129473A1 (en) * | 2017-07-21 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer |
| US11419856B2 (en) * | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| AU2019215450A1 (en) * | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| CN112262157A (zh) * | 2018-03-09 | 2021-01-22 | 加利福尼亚大学董事会 | 化药抗性癌症的组合治疗 |
| JP2022506829A (ja) * | 2018-11-09 | 2022-01-17 | ジー１、セラピューティクス、インコーポレイテッド | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214865B1 (en) | 1998-06-17 | 2001-04-10 | Eisai Co., Ltd. | Macrocyclic analogs and methods of their use and preparation |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| EP2522663B1 (en) | 2004-06-03 | 2015-04-01 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of halichondrin B |
| SI1853250T1 (sl) * | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| MX2008011978A (es) * | 2006-03-22 | 2009-04-22 | Medigene Ag | Tratamiento del cancer de seno negativo al triple receptor. |
| RU2489437C2 (ru) | 2007-10-03 | 2013-08-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Промежуточные соединения и способы синтеза аналогов галихондрина в |
| CN105801599A (zh) | 2008-04-04 | 2016-07-27 | 卫材R&D管理有限公司 | 软海绵素b类似物 |
| WO2011094339A1 (en) | 2010-01-26 | 2011-08-04 | Eisai R&D Management Co., Ltd. | Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs |
| EP2686441B1 (en) * | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| MX2015007185A (es) * | 2012-12-04 | 2017-09-05 | Eisai R&D Man Co Ltd | Uso de eribulina en el tratamiento de cancer de pecho. |
-
2013
- 2013-12-04 MX MX2015007185A patent/MX2015007185A/es unknown
- 2013-12-04 RU RU2015126539A patent/RU2689977C2/ru active
- 2013-12-04 JP JP2015544557A patent/JP6466339B2/ja active Active
- 2013-12-04 WO PCT/IB2013/002911 patent/WO2014087230A1/en not_active Ceased
- 2013-12-04 AU AU2013353745A patent/AU2013353745A1/en not_active Abandoned
- 2013-12-04 US US14/096,827 patent/US20140163095A1/en not_active Abandoned
- 2013-12-04 CA CA2892780A patent/CA2892780A1/en not_active Abandoned
- 2013-12-04 EP EP13826752.1A patent/EP2928464A1/en not_active Withdrawn
- 2013-12-04 BR BR112015012731A patent/BR112015012731A2/pt not_active Application Discontinuation
- 2013-12-04 KR KR1020157017971A patent/KR20150090921A/ko not_active Ceased
-
2015
- 2015-05-25 IL IL239007A patent/IL239007B/en active IP Right Grant
-
2018
- 2018-08-09 AU AU2018214086A patent/AU2018214086B2/en not_active Withdrawn - After Issue
-
2019
- 2019-01-09 JP JP2019002177A patent/JP6678783B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2689977C2 (ru) | 2019-05-30 |
| EP2928464A1 (en) | 2015-10-14 |
| IL239007B (en) | 2018-04-30 |
| AU2013353745A1 (en) | 2015-06-11 |
| US20140163095A1 (en) | 2014-06-12 |
| AU2018214086A1 (en) | 2018-08-23 |
| RU2015126539A (ru) | 2017-01-13 |
| IL239007A0 (en) | 2015-07-30 |
| WO2014087230A1 (en) | 2014-06-12 |
| JP2016501213A (ja) | 2016-01-18 |
| JP2019089776A (ja) | 2019-06-13 |
| CA2892780A1 (en) | 2014-06-12 |
| BR112015012731A2 (pt) | 2017-07-11 |
| JP6466339B2 (ja) | 2019-02-06 |
| AU2018214086B2 (en) | 2020-07-09 |
| KR20150090921A (ko) | 2015-08-06 |
| JP6678783B2 (ja) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| HRP20220897T8 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| PL2958945T3 (pl) | Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| SI3033086T1 (sl) | Kombinirana terapija za zdravljenje raka | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| PL3178849T3 (pl) | Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka | |
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| SI2766040T1 (sl) | Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke | |
| GEAP202114756A (en) | Combination therapy for the treatment of cancer | |
| IL276733A (en) | Use of Aribolin in cancer treatment | |
| MX2015011899A (es) | Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer. | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| PL3490560T3 (pl) | Niraparyb do stosowania w sposobie leczenia nowotworu prostaty | |
| UA117663C2 (uk) | Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози | |
| MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| HUE055132T2 (hu) | Virulenciában gyengített baktériumok rosszindulatú szolid tumorok kezelésére | |
| JOP20190056B1 (ar) | مركبات للاستخدام في علاج القصور الكلوي الحاد | |
| HUE054998T2 (hu) | Kombinációs terápiák emlõrák kezelésében való alkalmazásra | |
| IL290251A (en) | Combination for effective treatment of metastatic cancer in patients | |
| ZA201708686B (en) | Nanoparticles for use as a therapeutic vaccine | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
| CY1117438T1 (el) | Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης |